Back to search

FORNY20-FORNY2020

Market validation of new sample preparation solutions for clinical diagnostic purposes

Alternative title: Markedsvalidering av nye diagnostiske produkter for klinisk diagnostikk

Awarded: NOK 5.0 mill.

Project Number:

327262

Project Period:

2021 - 2022

Funding received from:

The aim with this project is to validate the market need of a novel sample preparation technology for clinical diagnostics. Lybe Scientific's first product; NAxtra- is a sample preparation solution for COVID-19 diagnostics both nationally and internationally during the pandemic. The technology has been shown to have very good performance within clinical diagnostics but the product needs to be further validated for a wider application area and for a wider selection of bacteria and viruses. The team will verify a more general solution for clinical diagnostics of respiratory pathogens as well as pathogens causing sexually transmitted diseases. The verification proposed in this application is a necessary market validation in order to position Lybe Scientific in the international market of diagnostics.

Extraction of nucleic acid from biological samples for diagnostic purposes is one of the most important achievements of modern science and is a basic necessity for almost all clinical diagnostic applications. With the application of high-throughput and automated extraction technology, the isolation process of nucleic acid is with this new solution greatly simplified. The business model is to produce and sell reagents to customers using state of art automation platforms in clinical laboratories and to offer disruptive pricing in order to offer the user economies of scale. We have developed our business modell further and entered into agreements with distributors for more efficient access to customers. The current project is well in line with UN sustainable development goal 3: Ensure healthy lives and promote well-being for all at all ages. In more detail, supplying solutions for sample preparation kits to the world will have a significant impact on goal 3.8, “…achieve access to quality essential health-care services and access to safe, effective, quality and affordable essential medicines and vaccines for all.” Our further business development will continue to be in line with this goal.

Funding scheme:

FORNY20-FORNY2020